Keywords: CEST / APT / NOE, CEST & MT, MRF, Glutamate, Parkinson's Disease
Motivation: Previous glutamate CEST-weighted studies were unable to separate the confounding effects stemming from different proton pools.
Goal(s): To develop a rapid and quantitative CEST MR Fingerprinting (MRF) pipeline for glutamate, amide, and semisolid MT imaging and validate it using a Parkinson’s disease (PD) mouse model.
Approach: An AI-based CEST-MRF framework was designed and used for imaging glutamate phantoms and MPTP PD mice (n=8).
Results: In-vitro maps were in excellent agreement with ground truth (r=0.95, p<0.0001). The in-vivo maps exhibited significant increases in the glutamate and MT concentrations following MPTP treatment, in agreement with MRS.
Impact: A multi-metabolite CEST-MRF quantitative approach was developed and validated using a mouse PD model. The extensive semisolid MT, amide and glutamate proton-exchange maps are expected to aid in the diagnosis and characterization of Parkinson’s disease.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords